BioCardia Announces Q4 2026 Target for CardiAMP Submission in Japan and Strategic Update

On June 18, 2026, BioCardia, Inc. issued a letter to shareholders outlining its strategic priorities and upcoming regulatory milestones. A primary focus for the company is the planned Shonin submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) in Q4 2026 for the CardiAMP Cell Therapy, targeting ischemic heart failure with reduced ejection fraction (HFrEF). The company highlights that Japan's status as a 'Reference Country' could expedite registration in other global regions. Additionally, BioCardia is advancing its confirmatory CardiAMP HF II Trial in the United States, which may support Premarket Approval (PMA). The company is also leveraging its Helix Transendocardial Delivery Catheter and Heart3D fusion imaging platform as a 'pipeline-in-a-product' to service other biotherapeutic programs. Financially, the company recently completed a capital raise intended to fund the Japan PMDA submission and continued U.S. clinical enrollment. Management also noted active discussions regarding strategic partnerships for its allogeneic mesenchymal stem cell (MSC) therapy platform and delivery technologies.